{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053791","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2026-08-06T10:34:40+00:00","discovered_at":"2026-08-06T10:35:00.293712+00:00","generated_at":"2026-08-06T10:35:08.615399+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zai Lab Q2 2026 revenue $106.3M, net loss $50.8M; pipeline advances with zoci and ZL-1503","bullets":["Total revenue $106.3M (down 3% YoY) but product revenue up 11% sequentially; net loss $50.8M ($0.46/ADS) vs $40.7M loss in Q2 2025.","R&D expenses rose to $61.8M (up 22% YoY) due to licensing fees; cash $717.5M as of June 30, 2026.","Zoci (DLL3 ADC) received FDA ODD for NECs and Fast Track for epNECs; Phase 1 data at ESMO 2026; registrational Phase 3 planned H2 2026.","ZL-1503 (IL-13/IL-31Rα) initial Phase 1 data expected H2 2026; KarXT launched in China; TIVDAK approved in China for cervical cancer.","VYVGART label expanded in US; partner Vertex's pove BLA accepted with PDUFA Nov 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053791","json":"https://secwatch.observer/filing/0001628280-26-053791.json","markdown":"https://secwatch.observer/filing/0001628280-26-053791.md","text":"https://secwatch.observer/filing/0001628280-26-053791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/0001628280-26-053791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T10:35:08.615399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}